Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem antibiotic presented as an injectable solution for intravenous use. It provides broad‑spectrum bactericidal activity for serious infections in hospitalized patients.\n\nGNH India supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious bacterial infections.\n\nComplicated intra‑abdominal infections: achieves rapid bacterial clearance and clinical resolution.\nComplicated urinary tract infections: eradicates resistant uropathogens and improves urinary sterility.\nHospital‑acquired pneumonia: provides effective coverage against multidrug‑resistant organisms.\nVentilator‑associated pneumonia: restores lung function by eliminating causative bacteria.\nMeningitis: penetrates the cerebrospinal fluid to treat central nervous system infections.\nSevere sepsis and septic shock: rapidly reduces bacterial load, supporting hemodynamic recovery.

Common Side Effects:\n- Nausea or vomiting\n- Diarrhea, which may be mild to moderate\n- Infusion‑site phlebitis or erythema\n- Headache\n- Elevated liver enzymes (ALT/AST)\n- Rash or mild skin irritation\n\nSerious or Rare Side Effects:\n- Seizures, especially in patients with renal impairment or CNS disorders\n- Clostridioides difficile‑associated colitis\n- Anaphylactic or severe hypersensitivity reactions\n- Acute renal toxicity or worsening renal function\n- Neutropenia or other severe hematologic abnormalities\n- Hepatotoxicity with marked liver enzyme elevation

Before initiating therapy, consider the following precautions.\n\nRenal function assessment: adjust dosing in patients with impaired renal clearance.\nAllergy assessment: avoid in individuals with known hypersensitivity to carbapenems or beta‑lactams.\nSeizure risk: monitor closely in patients with a history of seizures or CNS disorders.\nConcurrent valproic acid: avoid co‑administration as meropenem reduces valproate levels, increasing seizure risk.\nPregnancy and lactation: use only when the potential benefit justifies the potential risk to the fetus or infant.\nStore at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with other medicines; review the following.\n\nMajor Interactions (Avoid):\n- Valproic acid: meropenem markedly reduces plasma valproate concentrations, risking breakthrough seizures.\n- Other carbapenems: concurrent use can increase toxicity without added benefit.\n\nModerate Interactions (Monitor Closely):\n- Loop diuretics: may enhance nephrotoxic potential, requiring renal function monitoring.\n- Warfarin or other anticoagulants: may alter INR, necessitating more frequent coagulation testing.\n- Anticonvulsants such as phenytoin: may require dose adjustments due to altered plasma levels.